Orsiro DES

DEVICE2 trials

Sponsors

Biotronik, Inc.

Conditions

Acute Coronary SyndromeAngina PectorisAtherosclerosis, CoronaryCoronary Artery DiseaseIschemic Heart DiseaseMyocardial Ischemia

Unknown Phase

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

CompletedNCT02389946

Biotronik, Inc.Acute Coronary Syndrome, Angina Pectoris, Atherosclerosis, Coronary +3

Start: 2015-05-31End: 2021-03-31Updated: 2022-08-03

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

CompletedNCT04175626

Biotronik, Inc.Acute Coronary Syndrome, Angina Pectoris, Atherosclerosis, Coronary +3

Start: 2020-01-24End: 2026-01-08Updated: 2026-02-27

Related Papers

Impact of coronary artery tortuosity on outcomes following stenting with newer-generation drug-eluting stents. An analysis of the randomized BIOFLOW trials

Revista Española de Cardiología (English Edition)2025-01-05

Patients with higher-atherothrombotic risk vs. lower-atherothrombotic risk undergoing coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials.

2023-04-164 citations

Complex vs. non-complex percutaneous coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials.

2022-02-2510 citations

Impact of Coronary Calcification on Clinical Outcomes After Implantation of Newer‐Generation Drug‐Eluting Stents

Journal of the American Heart Association2021-05-2946 citations

Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis of individual patient data from 5 randomized trials.

2021-02-1716 citations

Individual patient data analysis of the BIOFLOW study program comparing safety and efficacy of a bioresorbable polymer sirolimus eluting stent to a durable polymer everolimus eluting stent

Catheterization and Cardiovascular Interventions2020-09-053 citations

Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions

Circulation Cardiovascular Interventions2020-09-0117 citations

Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.

2020-06-0160 citations

Cost and Mortality Implications of Lower Event Rates After Implantation of an Ultrathin-Strut Coronary Stent Compared With a Thin-Strut Stent Over Four Years.

2019-12-183 citations

Health Economic Evaluation of an Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Compared to a Thin, Durable-Polymer Everolimus-Eluting Stent.

2018-11-204 citations

Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents

Journal of the American College of Cardiology2018-09-2388 citations

Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients

Circulation Cardiovascular Interventions2018-09-2126 citations

Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.

2017-08-26194 citations